KP Tissue Reports Strong Q4 Results

Tissue company sees revenue growth, improved profitability, and progress on new U.S. facility

Published on Feb. 24, 2026

Got story updates? Submit your updates here. ›

KP Tissue and its Kruger Products subsidiary reported strong fourth-quarter and full-year 2025 results, including higher revenue, expanded profitability, and continued investment to support future capacity growth. The company highlighted momentum in both its consumer and away-from-home (AFH) segments, as well as progress toward a proposed new tissue facility in the western United States.

Why it matters

KP Tissue's performance reflects the company's ability to navigate industry challenges and capitalize on consumer demand for its tissue products. The planned new U.S. facility also signals the company's ambitions to expand its footprint and production capacity to meet future growth opportunities.

The details

For the fourth quarter, Kruger Products reported revenue of CAD 560.1 million, up 3.8% year-over-year, driven by higher sales volume in both the consumer and AFH segments. Adjusted EBITDA rose 26% to CAD 84.2 million, with an adjusted EBITDA margin of 15% compared to 12.4% a year earlier. The company cited several factors behind the improved profitability, including higher volume, better manufacturing productivity, lower pulp costs, and reduced freight rates.

  • For the fourth quarter of 2025, Kruger Products reported results.
  • In fiscal 2025, the company achieved 7.5% revenue growth and a 20.2% increase in adjusted EBITDA.
  • The company's new 'state-of-the-art' converting line in Memphis is on track for startup in early Q2 2026.

The players

Kruger Products

A subsidiary of KP Tissue Inc. that produces and sells a range of disposable tissue products in North America.

Dino Bianco

CEO of Kruger Products.

Michael Keays

CFO of Kruger Products.

Got photos? Submit your photos here. ›

What they’re saying

“Revenue growth was 'well diversified' between Canada and the U.S., noting that the U.S. comparison was difficult because revenue was up nearly 20% in the prior-year quarter.”

— Dino Bianco, CEO

“I view the AFH business as a sustainable model and suggested that while quarterly results can be volatile, the segment should be 'in the low double digits' on a long-term margin basis.”

— Dino Bianco, CEO

What’s next

The company is finalizing details for a proposed new TAD tissue plant in the western United States slated to open in 2028 and anticipates a detailed announcement in the first half of 2026.

The takeaway

KP Tissue's strong financial performance and continued investment in capacity expansion demonstrate the company's ability to navigate industry challenges and capitalize on growing consumer demand for its tissue products. The planned new U.S. facility signals the company's ambitions to expand its footprint and production capabilities to meet future growth opportunities.